|
Synonyms: HuMax-TF-ADC | TF-011-MMAE | tisotumab vedotin-tftv | Tivdak®
tisotumab vedotin is an approved drug (FDA (2021))
Compound class:
Antibody
Comment: Tisotumab vedotin is an antibody-drug conjugate (ADC) of an anti-factor 3 monoclonal antibody that is conjugated to the antineoplastic agent monomethyl auristatin E (MMAE; PubChem CID 11542188) [1]. Tisotumab vedotin causes adverse events that are associated with disrupted coagulation [4].
|
| Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
